Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Working Capital Changes: 2018-2024

Historic Other Working Capital Changes for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to $9.7 million.

  • Revolution Medicines' Other Working Capital Changes rose 111.87% to $517,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 261.74%. This contributed to the annual value of $9.7 million for FY2024, which is 317.49% up from last year.
  • Per Revolution Medicines' latest filing, its Other Working Capital Changes stood at $9.7 million for FY2024, which was up 317.49% from -$4.5 million recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Other Working Capital Changes registered a high of $9.7 million during FY2024, and its lowest value of -$14.5 million during FY2022.
  • Its 3-year average for Other Working Capital Changes is -$3.1 million, with a median of -$4.5 million in 2023.
  • Per our database at Business Quant, Revolution Medicines' Other Working Capital Changes slumped by 771.28% in 2022 and then spiked by 317.49% in 2024.
  • Yearly analysis of 5 years shows Revolution Medicines' Other Working Capital Changes stood at -$11.3 million in 2020, then spiked by 85.25% to -$1.7 million in 2021, then crashed by 771.28% to -$14.5 million in 2022, then skyrocketed by 69.19% to -$4.5 million in 2023, then surged by 317.49% to $9.7 million in 2024.